Loading
Life sciences · Journal article
Cancer · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Background Early favorable prostate‐specific antigen (PSA) response to ≤0.2 ng/mL by 6 months is associated with superior overall survival (OS) in metastatic hormone‐sensitive prostate cancer (mHSPC). The nadir androgen receptor pathway inhibitor (ARPI)‐derived integrative response (NADIR) model is a multivariable model developed to predict this early favorable PSA response in patients receiving ARPI. The authors report an independent external validation of the locked NADIR model in the ARCHES trial. Methods Of 574 enzalutamide‐treated patients, 558 with complete predictors were included. Discrimination, Brier score/index of prediction accuracy (IPA), and calibration were assessed. Predicted probability tertiles were used descriptively for PSA response. Six‐month landmark Cox models explored associations with OS. A sensitivity analysis restricted the cohort to <3 months of prior androgen deprivation therapy (ADT). Results Early favorable PSA response occurred in 359 patients (64%). The area under the receiver operating characteristic curve was 0.80 (95% confidence interval [CI], 0.76–0.83), the Brier score was 0.17, and the IPA was 25%. Recalibration intercept was 0.026 and slope was 0.97. Response rates across decreasing predicted probability tertiles were 92%, 64%, and 37%. In the landmark analysis ( n = 547; 177 deaths), each 10‐percentage‐point increase in predicted probability was associated with lower mortality (hazard ratio, 0.90; 95% CI, 0.85–0.96). In the <3‐month prior‐ADT subgroup ( n = 401), the area under the receiver operating characteristic curve and IPA were 0.78 and 23%, respectively. Conclusions The NADIR model demonstrates robust and reproducible discrimination, calibration, and prognostic stratification in a distinct ARPI‐treated mHSPC cohort, supporting its potential utility for early response risk stratification and trial enrichment pending prospective validation of model‐guided treatment adaptation.